Last updated: April 25, 2026
Who supplies Copaxone (glatiramer acetate) and where do the sourcing constraints sit?
Copaxone is a branded formulation of glatiramer acetate, a complex mixture of synthetic polypeptides used for relapsing forms of multiple sclerosis. In practice, “suppliers” in the Copaxone value chain split into (1) active pharmaceutical ingredient (API) and (2) finished-dose manufacturing and packaging, with (3) a separate set of entities supplying fill-finish materials and primary packaging (where disclosed in regulatory filings, labeling, and manufacturing records).
Because the question requests “suppliers” without scoping to a specific geography (US/EU) or a specific Copaxone presentation (for example 20 mg/mL three times weekly vs 40 mg/mL three times weekly), the only defensible answer is to map suppliers by regulatory-identified manufacturing roles at the product level.
What supply roles matter for Copaxone?
| Value-chain layer |
Typical “supplier” in the paperwork |
Why it matters |
| API |
API manufacturer(s) named in regulatory submissions and inspection histories |
Sets chemical quality and traceability for batch release |
| Drug product (DP) |
Contract manufacturer(s) for sterile injection manufacturing and batch release |
Controls GMP compliance, aseptic process capability, and yields |
| Packaging |
Primary packaging suppliers for syringes, plungers, labels, cartons |
Impacts device compatibility, leachables, and cold-chain stability |
| Logistics |
Wholesaler/distributor and importers in each market |
Governs market availability and lead-time risk |
Who is listed as manufacturing supply for Copaxone?
Copaxone’s ownership is linked to Teva’s branded portfolio. In the US, the product is marketed by Teva Pharmaceuticals USA, Inc. and the injection is manufactured under GMP by Teva and/or its contract manufacturing partners as identified in product labeling and FDA product listings. The cleanest “supplier” statement is limited to entities that appear as product holders and manufacturing sites in regulator-facing records.
- Teva Pharmaceuticals USA, Inc.: US product marketer (labeling/holder entity).
- Teva API and drug product manufacturing sites: Teva has historically manufactured glatiramer acetate and sterile drug product through its network and suppliers in the Teva manufacturing footprint used for sterile injectable MS therapies.
- Syringe and injection assembly suppliers: typically suppliers of preassembled syringe components and/or sterile fill-finish support where documented in manufacturing records.
What this means operationally: for Copaxone, the “supplier list” is not one company; it is the set of named parties who manufacture and release the API and the sterile drug product plus the primary packaging format (the prefilled syringe system).
Practical supplier map used for due diligence
Below is the supplier mapping structure used by investors and R&D procurement teams to qualify continuity risk for Copaxone-like sterile injectables. It is framed as roles because that is how regulator records identify supply responsibility.
1) API supply (glatiramer acetate)
Supplier expectation: API is produced under GMP by the originator brand’s API manufacturing arm or a dedicated API contract site. For Copaxone, the API manufacturing is tied to Teva’s global supply chain for glatiramer acetate.
Due diligence targets:
- API batch release site identity
- Sterility is not relevant at API stage, but impurity profile and endotoxin limits are
- Polymer mixture characterization controls (molecular weight distribution, sequence composition) and batch-to-batch comparability
2) Drug product (sterile injection) supply
Supplier expectation: sterile aseptic fill-finish and final DP batch release are performed by Teva and/or contract manufacturers specialized in sterile injectables.
Due diligence targets:
- Aseptic processing line qualification and contamination control record
- Container closure integrity testing capability for the prefilled syringe format
- Sterility assurance approach for a peptide mixture (risk assessment coverage)
3) Primary packaging supply
Supplier expectation: prefilled syringe components (syringe barrel, stopper, needle assembly where present, labeling compatibility materials).
Due diligence targets:
- Rubber/plunger component extractables and leachables profile alignment
- Compatibility with glatiramer acetate formulation and storage conditions
- Label ink adhesion and scannability tolerances (where packaging is part of batch release)
How to treat “generic Copaxone” supply
Copaxone has multiple approved equivalents across markets. “Suppliers” therefore diverge depending on whether the inquiry targets:
- Brand Copaxone (Teva label holder) vs
- Authorized generics (if applicable) vs
- Unauthorised imports (not suitable for compliant supply chains)
In compliant procurement, “supplier identity” is tied to the approved drug product in each market and its labeled manufacturer and importer.
Key Takeaways
- Copaxone’s supply chain is role-based: API manufacturer, sterile drug product (aseptic fill-finish and DP release) manufacturer, and primary packaging suppliers tied to the prefilled syringe system.
- The most reliable supplier anchor for the US is the labeled product holder/marketer: Teva Pharmaceuticals USA, Inc., with manufacturing performed at GMP sites identified in regulator-facing records.
- Any investment or procurement “supplier list” for Copaxone must be built from named manufacturing sites and packaging participants tied to the exact market and presentation, because supplier identity varies by jurisdiction and strength.
FAQs
1) Who makes the active ingredient in Copaxone?
The active ingredient is glatiramer acetate, manufactured under GMP by Teva’s API supply chain or named GMP API sites used for the brand’s supply.
2) Who fills and finishes Copaxone injections?
Aseptic sterile drug product (fill-finish) and batch release is performed by Teva and/or designated GMP sterile injectable manufacturing sites for the prefilled syringe presentation used in the market.
3) Are syringe component suppliers part of the Copaxone supplier roster?
Yes, primary packaging component suppliers (syringe and stopper system and compatible labels) are part of the procurement and qualification chain for the prefilled injection.
4) Does supplier identity change between Copaxone 20 mg and 40 mg?
Supplier mapping can change by presentation because formulation hold times, fill line setup, and packaging specifications differ by strength.
5) Does the supplier list match for generics and the brand?
No. Approved generics may use different manufacturing sites and packaging systems while delivering the same active ingredient, so the supplier roster differs.
References (APA)
[1] Teva Pharmaceuticals USA, Inc. Copaxone product labeling / US product information (FDA label and product listing documents).
